Silo Pharma, Inc. announced that its Alzheimer?s disease therapeutic SPC-14 showed positive efficacy in small animals. Data from a study conducted at Columbia University in collaboration with Silo Pharma showed that SPC-14 was effective against LH stress in attenuating learned helplessness, perseverative behavior, and hyponeophagia (a measure of anxiety). The mice were treated twice daily with the SPC-14 therapeutic.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.85 USD | 0.00% | 0.00% | +28.47% |
Apr. 23 | Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment | CI |
Apr. 10 | Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+28.47% | 5.26M | |
-3.79% | 88.14B | |
+1.45% | 40.51B | |
-15.94% | 31.67B | |
+52.66% | 24.62B | |
-14.50% | 15.65B | |
-9.12% | 11.97B | |
-14.38% | 12.07B | |
-42.56% | 11.61B | |
+4.87% | 8.81B |
- Stock Market
- Equities
- SILO Stock
- News Silo Pharma, Inc.
- Silo Pharma Announces Positive Results in Alzheimer?s Disease Study